Faustino TorricoFabiana BarreiraNathalie Strub‐WourgaftIsabella RibeiroSergio Sosa‐Estáni2026-03-222026-03-22202110.1016/s1473-3099(21)00336-4https://doi.org/10.1016/s1473-3099(21)00336-4https://andeanlibrary.org/handle/123456789/86889Citaciones: 2enBenznidazoleDiscontinuationAdverse effectRegimenPlaceboMedicineInternal medicinePopulationBenznidazole in Chagas disease study: do the data justify progression to phase 3? – Authors’ replyletter